BF-200 ALA

DRUG3 trials

Sponsors

Biofrontera Bioscience GmbH

Conditions

Actinic KeratosisBasal Cell Carcinoma (BCC)

Phase 3

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

CompletedNCT02144077

Biofrontera Bioscience GmbHBasal Cell Carcinoma (BCC)

Start: 2014-01-28End: 2020-09-09Updated: 2022-11-03

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

CompletedNCT02799082

Biofrontera Bioscience GmbHActinic Keratosis

Start: 2007-12-31End: 2008-10-31Updated: 2017-04-06

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

CompletedNCT02799069

Biofrontera Bioscience GmbHActinic Keratosis

Start: 2008-04-30End: 2009-08-31Updated: 2017-04-28